BioAdaptives (BDPT) 10-Q2024 Q2 Quarterly report

Filed: 19 Aug 24, 9:22am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: apparent, bringing, const, dieting, dog, dosing, Empowering, healthy, impairment, incorrect, lose, mice, ongoing, prove, repair, simple, situation, statement, unpredictable, unrealized, user, vary, weight, Wynovia, Xcellera, Zeranovia

Removed: adhere, administration, applied, assist, assumption, boarding, coat, cognition, compete, conservatively, consistently, critical, discontinue, emotional, employing, enable, energy, enhancement, external, fatigue, generating, hair, healing, hoof, improved, increasing, incurring, independent, induced, mane, March, monitor, nail, packaging, physical, positive, PrimiSleep, profit, profitably, qualitative, quantitative, recoverability, reduction, Rejuven, relaxation, respiratory, reverse, satisfying, scale, science, soporific, source, sphere, subjective, supplemental, underlying, understand, variable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BDPT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

BIOADAPTIVES INC.CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James Keener, Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Robert W. Ellis and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: August 19, 2024		/s/James Keener
		James Keener
		Principal Accounting Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.